REDWOOD CITY, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) will present new data from the company's Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18) at the 5th European Lung Cancer Conference (ELCC) being held April 15-18, 2015 in Geneva, Switzerland.
The Phase 1b clinical trial was designed to assess the safety, tolerability and efficacy of demcizumab combined with pemetrexed and carboplatin in patients with first-line metastatic non-small cell lung cancer (NSCLC). Results to be presented at the ELCC meeting will include new data on the safety of the three drug combination administered at the chosen Phase 2 dose, as well as overall survival, progression-free survival, response rate and pharmacodynamic endpoints.
April 16, 2015 12:30 pm – 1:10 pm
"A Phase 1b study of anti-DLL4 (delta-like ligand 4) antibody demcizumab (DEM) with pemetrexed (PEM) and carboplatin (CARBO) in patients with 1st-line non-squamous NSCLC"
Abstract Number: 114
Presenting author: Jakob Dupont, M.D., Senior Vice President, Chief Medical Officer, OncoMed Pharmaceuticals
In January 2015, OncoMed dosed the first patient in the randomized Phase 2 "DENALI" clinical trial of demcizumab in patients with advanced first-line NSCLC. The Phase 2 trial will compare the efficacy and safety of one or two truncated courses of demcizumab in combination with pemetrexed and carboplatin against pemetrexed, carboplatin and placebo.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, the most advanced of which are in randomized Phase 2 clinical trials. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28) each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed plans to file an Investigational New Drug application during the first half of 2015 for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immuno-oncology product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.
CONTACT: Media & Investors OncoMed Pharmaceuticals Michelle Corral Senior Director, Investor Relations and Corporate Communications firstname.lastname@example.org (650) 995-8373 Investors Shari Annes Annes Associates email@example.com (650) 888-0902
Source:OncoMed Pharmaceuticals, Inc.